A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia Subjects With Inadequate Control on Febuxostat
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Febuxostat (Primary) ; Ruzinurad (Primary)
- Indications Gout; Hyperuricaemia
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 15 Jun 2024 Primary endpoint has been met. (Proportion of subjects with serum uric acid 360mol/L)
- 15 Jun 2024 Status has been changed to completed
- 15 Jun 2024 Results presented at the 25th Annual Congress of the European League Against Rheumatism